Media contact: Stéphanie Bardon – communication@genethon.fr – 01.69.47.12.78
November 19, 2024
Genethon Presents Positive Initial Results from a Phase 1/2/3 Trial of its Gene Therapy (GNT0004) for Duchenne Muscular Dystrophy at ASGCT Breakthroughs in Muscular Dystrophy in Chicago
October 21, 2024
Genethon to Showcase the Latest Advances in Gene Therapies for Multiple Diseases at the ESGCT 31st Annual Congress October 22 – 25, 2024 in Rome, Italy
September 17, 2024
Genethon and Samabriva strengthen their partnership to develop of a cost-effective plant-based AAV manufacturing process for greater patient access to gene therapies.
September 12, 2024
Genethon Announces Publication in Nature Communications of a Next-Generation Gene Therapy Vector for Muscle Diseases, Using AI Predictive Methodology to Improve Efficacy and Safety
September 6, 2024
Marking World Duchenne Muscular Dystrophy Day, Genethon Reaffirms Its Commitment to Helping Patientsfor 35 years and Provides an Update on Its PromisingGene Therapy Drug Candidate for This Fatal Disease
May 3, 2024
Genethon’s Scientists Featured in Multiple Presentations at American Society of Gene & Cell Therapy Annual Meeting May 7-11, 2024, in Baltimore, MD
April 29, 2024
GenoTher, biocluster in the field of gene therapy is officially launched
April 23, 2024
First Clinical Trial Results of Gene Therapy (GNT0004) for Duchenne Muscular Dystrophy presented at International Myology 2024 Congress
April 22, 2024
Genethon will introduce its latest advances in gene therapy research in multiple presentations at the International Myology 2024 Congress
February 28, 2024
Genethon Pursues Different Strategies for Ensuring Patient Access to Gene Therapies for Rare Diseases
November 17, 2023
Clinical results of the gene therapy trial in myotubular myopathy : efficacy on respiratory and motor functions in this extremely severe disease, challenges ahead
October 24, 2023
The Latest Research of 14 Généthon Scientists to be Featured at the European Society of Gene & Cell Therapy’s 30th Annual Congress, Oct. 24-27, 2023, in Brussels, Belgium
August 17, 2023
First results of Crigler-Najjar clinical trial published in New England Journal of Medicine
July 12, 2023
